Hoth Therapeutics issues 2M shares of Series B Preferred with 10-to-1 voting for $1,000

Hoth Therapeutics, Inc.

Sold 2,000,000 Series B Preferred shares to a single investor for aggregate $1,000; shares have $0.0001 par value.
Each Series B share carries 10 votes, voting only on Authorized Stock Increase; no dividend or liquidation rights.
Series B Preferred automatically redeemed for $10 upon effectiveness of Authorized Stock Increase or at board's discretion.
Shares issued in unregistered transaction relying on Section 4(a)(2) exemption.
Certificate of Designation filed in Nevada to create the new series.

item 1.01 item 3.02 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Hoth Therapeutics, Inc.: Created Series B Preferred Stock, designating 2,000,000 shares (effective 2022-11-02).

Change: charter amendment
Effective: 2022-11-02

Exact text from the filing

On November 2, 2022, the Company filed a Certificate of Designation of the Series B Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Nevada to create a new class of Series B Preferred Stock, par value $0.0001 per share.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Hoth Therapeutics, Inc. entered into Subscription Agreement with an investor valued at $1,000 (effective 2022-11-02).

Action: entry
Agreement: equity purchase
Counterparty: an investor
Value: $1,000
Effective: 2022-11-02

Exact text from the filing

On November 2, 2022, Hoth Therapeutics, Inc. (the “Company”) entered into a Subscription and Investment Representation Agreement (the “Subscription Agreement”) with an investor (the “Purchaser”) pursuant to which it issued and sold 2,000,000 shares (the “Shares”) of the Company’s newly designated Series B Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”), to such Purchaser for an aggregate purchase price of $1,000.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Hoth Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-068985

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.